Literature DB >> 6938517

Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.

S Seeber, H Loth, S T Crooke.   

Abstract

The kinetics of cellular and nuclear incorporation of a number of new anthracyclines into daunorubicin-sensitive and -resistant Ehrlich ascites cells were determined in vitro. For comparative quantitative analyses the substances were extracted with a 0.3 N HCl/50% ethanol (v/v) solution from either whole cells or purified citric acid nuclei after various intervals of in vitro incubation. At steady state the intracellular and intranuclear concentrations of daunorubicin and doxorubicin were reduced by about 50% in the resistant cell line. Marcellomycin and carminomycin concentrations were only reduced by 9% and 11%, respectively, and no differences between sensitive and resistant cells were seen in the case of aclacinomycin A and AD 32. When the ratios of nuclear to cellular drug were determined at steady state lowest value was found for AD 32 (0.26). In contrast, aclacinomycin A and carminomycin were mainly (78% and 74%) and marcellomycin almost exclusively (95%) concentrated in the nucleus. When the total amounts of drug incorporated per cell were compared, the highest values were measured for aclacinomycin A and the lowest for AD 32 both in the sensitive and the resistant tumor. Additional determinations of the 50% inhibitory concentrations for thymidine uptake showed similar differences between these anthracyclines which were not related to the potency of the drugs in vivo. It is concluded that apart from nuclear incorporation and inhibition of DNA synthesis other factors may be decisive for anthracycline-induced cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6938517     DOI: 10.1007/bf00405955

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

1.  Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.

Authors:  T Skovsgaard
Journal:  Biochem Pharmacol       Date:  1977-02-01       Impact factor: 5.858

2.  Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumor in vivo.

Authors:  K Danø
Journal:  Cancer Chemother Rep       Date:  1972-06

3.  Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response.

Authors:  D Kessel; V Botterill; I Wodinsky
Journal:  Cancer Res       Date:  1968-05       Impact factor: 12.701

4.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04

5.  Structure-activity relationships of anthracyclines relative to effects on macromolecular syntheses.

Authors:  S T Crooke; V H Duvernay; L Galvan; A W Prestayko
Journal:  Mol Pharmacol       Date:  1978-03       Impact factor: 4.436

6.  The antitumor effects of anthracyclines. The importance of the carbomethoxy-group at position-10 of marcellomycin and rudolfomycin.

Authors:  V H DuVernay; J M Essery; T W Doyle; W T Bradner; S T Crooke
Journal:  Mol Pharmacol       Date:  1979-03       Impact factor: 4.436

7.  Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Authors:  A Krishan; M Israel; E J Modest; E Frei
Journal:  Cancer Res       Date:  1976-06       Impact factor: 12.701

8.  Deoxyribonucleic acid binding studies on several new anthracycline antitumor antibiotics. Sequence preference and structure--activity relationships of marcellomycin and its analogues as compared to adriamycin.

Authors:  V H DuVernay; J A Pachter; S T Crooke
Journal:  Biochemistry       Date:  1979-09-04       Impact factor: 3.162

9.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Authors:  M Inaba; H Kobayashi; Y Sakurai; R K Johnson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

10.  New anthracycline antibiotics.

Authors:  T Oki
Journal:  Jpn J Antibiot       Date:  1977-12
View more
  6 in total

1.  Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells.

Authors:  S Seeber; H Loth
Journal:  Blut       Date:  1981-06

2.  Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.

Authors:  A Zenebergh; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Positive correlation between decreased cellular uptake, NADPH-glutathione reductase activity and adriamycin resistance in Ehrlich ascites tumor lines.

Authors:  M E Scheulen; H Hoensch; H Kappus; S Seeber; C G Schmidt
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

4.  Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells.

Authors:  L Kleeberger; E M Röttinger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.

Authors:  J M Millot; T D Rasoanaivo; H Morjani; M Manfait
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

6.  Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.

Authors:  G J Schuurhuis; T H van Heijningen; A Cervantes; H M Pinedo; J H de Lange; H G Keizer; H J Broxterman; J P Baak; J Lankelma
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.